BNET Industries
Last Fiscal Year Sales:$1.2M
- Public
- US
Dow Jones Description
During the past two years, we have refocused our efforts on the development of medical imaging agents, including cardiovascular and lymphography contrast imaging agents. We accomplished this shift in focus by splitting off our therapeutic line of business, as more fully described in ?Recent Developments? below. We are currently an emerging, development-stage biopharmaceutical company focused on developing a novel contrast agent with potential applications (1) as a blood pool agent, to diagnose diseased tissue in the cardiovascular system and other organs, and (2) to diagnose cancer metastasizing into the lymphatic system. We are the exclusive licensee of a group of proprietary materials, the lead compound of which is a contrast agent we refer to as PH-50 or N1177. We established the two names to distinguish commercialization rights between cardiovascular imaging (and all other indications) (PH-50) to which we retain rights, and the field of lymphography (N1177), which we licensed to our joint venture (Sentigen, Ltd.) with affiliates of Elan Corporation, plc (?Elan?).
Director, Chairman
Lester H McKeever JrContact Information
6175 Lusk Boulevard
San Diego, California 92121
858 410-5601
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
News & Analysis
Filter by
imcor pharmaceutical co. - All News and Analysis
IMCOR Pharmaceutical Co. Receives Notice of Allowance of IMCOR's Patent Application for Imagent Entitled - ''Mixed Gas Microbubble Composition''
SAN DIEGO -- IMCOR Pharmaceutical Co. (Pink Sheets:ICRP) today announced that the U.S. Patent and Trademark Office USPTO issued a notification of allowance for a patent directed to the composition of matter of forming stabilized microbubbles using mixed gases. The technology reflected in the patent is used for ultrasound contrast...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Alan Watson | Director |
| Robert J Weinstein | Director |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Lester H McKeever Jr | Director, Chairman |
| Jonathan Fleming | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| Imcor Pharmaceutical Co | Director, Chairman | Current |
| Organization | Position | Status |
|---|---|---|
| Centagenetix, Inc. | Executive Vice President and Chief Business Officer | Current |
| Targeted Diagnostics & Therapeutics, Inc. | Executive Vice President, Chief Business Officer | Current |
| Smartcells Inc | Vice President of Business Development | Current |
| Optimum Percussion | Managing Director | Current |
| Imcor Pharmaceutical Co | Director | Current |
| Elixir Pharmaceuticals, Inc. | Chief Business Officer | Former |
| Elixir Pharmaceuticals, Inc. | Executive Vice President | Former |
| Northeastern University | Ph.D. In Bioinorganic Chemistry | Former |
| National University | Ph.D. In Bioinorganic Chemistry | Former |
| Northeastern University | M.B.A. | Former |
| University of NSW | B.Sc. | Former |
| University Corp. | B.Sc. | Former |
Jonathan J. Fleming is one of our co-founders and is Chairman of our Board of Directors. Mr. Fleming served as Chairman from January 1998 to May 2005 and assumed the position again in October 2006. Mr. Fleming has served as the Managing Partner of Oxford Bioscience Partners, a venture capital firm specializing in life science technology since 1996. Prior to joining Oxford Bioscience, he served as a Founding Partner of MVP Ventures in Boston, Massachusetts. Mr. Fleming serves as a member of the board of directors of Imcor Pharmaceutical Co. (formerly Photogen Technologies, Inc.), a specialty pharmaceutical company focused on developing medical imaging pharmaceutical products. He also serves as Chairman of the board of directors of BioProcessors Corporation, a privately-held corporation, and as a director of seven other privately-held companies, including Leerink Swann & Company, Inc., a Boston-based investment bank specializing in health care companies. Mr. Fleming is a Trustee of the Museum of Science in Boston and is a Senior Lecturer at Massachusetts Institute of Technology's Sloan School of Management. Mr. Fleming received a B.A. from the University of California, Berkeley and a Masters in Public Administration from Princeton University.
| Organization | Position | Status |
|---|---|---|
| Memory Pharmaceuticals Corp. | Co-Founder | Current |
| Oxford Bioscience Partners | Managing Partner | Current |
| MIT Sloan School of Management | Senior Lecturer | Current |
| Leerink Swann & Company | Managing Partner of Oxford Bioscience Partners | Current |
| Massachusetts Life Sciences Collaborative | Managing General Partner, Oxford Bioscience Partners | Current |
| Hypnion, Inc. | Current | |
| Centagenetix, Inc. | Current | |
| The Convergence Forum | Current | |
| BioProcessors Corp. | Chairman | Current |
| Braincells, Inc. | Board of Directors | Current |
| Memory Pharmaceuticals Corp. | Chairman of the Board | Current |
| Railrunner | Board of Directors | Current |
| Asterand, Plc. | Board of Directors | Current |
| Museum of Science | Board of Directors | Current |
| Elixir Pharmaceuticals, Inc. | Board of Directors | Current |
| Nehi | Board of Directors | Current |
| Alta Partners | Director | Current |
| Synaptic Pharmaceutical Corp | Director | Current |
| Leerink Swann & Company | Board of Directors | Current |
| Museum of Science | Trustee | Current |
| Medica Venture Partners | Co-Founder | Former |
| MVP Ventures | Founding General Partner | Former |
| Medica Venture Partners | Special Limited Partner | Former |
| Tvm Techno Venture Management | General Partner | Former |
| Oxford Bioscience Partners | Owner | Former |
| Biotechnology Venture Investors Group | Chairman | Former |
| Princeton University | Master's Degree In Public Administration | Former |
| University of California, Berkeley | Master's Degree In Public Administration | Former |
| University of California, Berkeley | Bachelor of Arts Degree | Former |
| University of California | B.A. | Former |
| Organization | Position | Status |
|---|---|---|
| Imcor Pharmaceutical Co | Director | Current |
Industry Transcripts by Seeking Alpha
-
Peregrine Pharmaceuticals Inc. F2Q10 (Qtr End 31/10/09) Earnings Call Transcript
on Dec 10, 2009about PPHM
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
- Why J&J's Stelara Launch Should Target Dermatologists First 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes


